BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17126871)

  • 1. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
    Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
    Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
    Soros VB; Yonemoto W; Greene WC
    PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited.
    Cadima-Couto I; Freitas-Vieira A; Nowarski R; Britan-Rosich E; Kotler M; Goncalves J
    Virology; 2009 Oct; 393(2):286-94. PubMed ID: 19717177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Schäfer A; Bogerd HP; Cullen BR
    Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of APOBEC3G-positive 293T cells for HIV-1 Vif study.
    Piroozmand A; Yamamoto Y; Khamsri B; Fujita M; Uchiyama T; Adachi A
    J Med Invest; 2007 Feb; 54(1-2):154-8. PubMed ID: 17380027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein.
    Pery E; Sheehy A; Nebane NM; Brazier AJ; Misra V; Rajendran KS; Buhrlage SJ; Mankowski MK; Rasmussen L; White EL; Ptak RG; Gabuzda D
    J Biol Chem; 2015 Apr; 290(16):10504-17. PubMed ID: 25724652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.
    Ao Z; Yu Z; Wang L; Zheng Y; Yao X
    PLoS One; 2008 Apr; 3(4):e1995. PubMed ID: 18414671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional domains of APOBEC3G required for antiviral activity.
    Li J; Potash MJ; Volsky DJ
    J Cell Biochem; 2004 Jun; 92(3):560-72. PubMed ID: 15156567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GANP interacts with APOBEC3G and facilitates its encapsidation into the virions to reduce HIV-1 infectivity.
    Maeda K; Almofty SA; Singh SK; Eid MMA; Shimoda M; Ikeda T; Koito A; Pham P; Goodman MF; Sakaguchi N
    J Immunol; 2013 Dec; 191(12):6030-6039. PubMed ID: 24198285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.
    Britan-Rosich E; Nowarski R; Kotler M
    J Mol Biol; 2011 Jul; 410(5):1065-76. PubMed ID: 21763507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.
    Thangavelu PU; Gupta V; Dixit NM
    Virology; 2014 Jan; 449():224-8. PubMed ID: 24418556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
    Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
    Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    Tian C; Yu X; Zhang W; Wang T; Xu R; Yu XF
    J Virol; 2006 Mar; 80(6):3112-5. PubMed ID: 16501124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
    Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
    J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Stopak K; de Noronha C; Yonemoto W; Greene WC
    Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.